Spots Global Cancer Trial Database for Immune Response to the COVID-19 Vaccine

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Immune Response to the COVID-19 Vaccine

Official Title: Immune Response to the COVID-19 Vaccine

Study ID: NCT04936997

Conditions

Covid19

Cancer

Malignancy

Vaccine Response Impaired

Interventions

SARS-COV2 Pfizer Vaccine

Study Description

Brief Summary: Explore the effects on immune response to include a potential third vaccine for the cancer cohort.

Detailed Description: In recent work performed by the University of Arizona Cancer Center team, 59 patients with a known diagnosis of a solid tumor malignancy on active immunosuppressive cancer therapy were enrolled through the University of Arizona Cancer Center during their routine care. These subjects had a decreased response with the vaccine when compared to the health cohort. The investigators are amending this study to explore the effects on immune response to include a potential third vaccine for the cancer cohort. This will increase the visits required to approximately two more visits. It will require two additional blood samples, one 48 hours prior to third vaccine and the second, 5-11 days after the third vaccine. The following protocol will be for the subjects that decide to continue onto a third vaccination.